101 related articles for article (PubMed ID: 23017888)
1. 4-Substituted-2-phenylquinazolines as inhibitors of BCRP.
Juvale K; Wiese M
Bioorg Med Chem Lett; 2012 Nov; 22(21):6766-9. PubMed ID: 23017888
[TBL] [Abstract][Full Text] [Related]
2. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
Juvale K; Gallus J; Wiese M
Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Juvale K; Stefan K; Wiese M
Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
[TBL] [Abstract][Full Text] [Related]
4. Design of inhibitors of BCRP/ABCG2.
Juvale K; Wiese M
Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
[TBL] [Abstract][Full Text] [Related]
5. Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein.
Juvale K; Pape VF; Wiese M
Bioorg Med Chem; 2012 Jan; 20(1):346-55. PubMed ID: 22112540
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
7. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
9. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
Zhang S; Yang X; Coburn RA; Morris ME
Biochem Pharmacol; 2005 Aug; 70(4):627-39. PubMed ID: 15979586
[TBL] [Abstract][Full Text] [Related]
10. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
Liu XL; Tee HW; Go ML
Bioorg Med Chem; 2008 Jan; 16(1):171-80. PubMed ID: 17964170
[TBL] [Abstract][Full Text] [Related]
11. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).
Matsson P; Englund G; Ahlin G; Bergström CA; Norinder U; Artursson P
J Pharmacol Exp Ther; 2007 Oct; 323(1):19-30. PubMed ID: 17616561
[TBL] [Abstract][Full Text] [Related]
12. Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
Gu X; Ren Z; Peng H; Peng S; Zhang Y
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):318-22. PubMed ID: 25446092
[TBL] [Abstract][Full Text] [Related]
13. Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
Pick A; Müller H; Wiese M
Bioorg Med Chem Lett; 2010 Jan; 20(1):180-3. PubMed ID: 19932960
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
15. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
[TBL] [Abstract][Full Text] [Related]
16. Scaffold identification of a new class of potent and selective BCRP inhibitors.
Marighetti F; Steggemann K; Karbaum M; Wiese M
ChemMedChem; 2015 Apr; 10(4):742-51. PubMed ID: 25735648
[TBL] [Abstract][Full Text] [Related]
17. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
18. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
Pick A; Müller H; Wiese M
Bioorg Med Chem; 2008 Sep; 16(17):8224-36. PubMed ID: 18678495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]